The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Hintergrund Patienten mit Typ-2-Diabetes haben ein erhöhtes kardiovaskuläres Risiko. Neben der Einstellung des Blutglukosespiegels profitieren sie insbesondere von einer strengen LDL-Cholesterin-Senkung (LDL: „low density lipoprotein“). Minderung des kardiovaskulären Risikos Bisher wurden für die LDL-Cholesterin-Senkung primär hochpotente Statine empfohlen. In der IMPROVE-IT-Studie konnte nun erstmals...
Hintergrund Bei Typ-2-Diabetes ist das Risiko, an kardiovaskulären Erkrankungen zu versterben, trotz optimaler antihypertensiver und lipidsenkender Therapie massiv erhöht. Studien In großen Studien wie ADVANCE („action in diabetes and vascular disease: preterax and diamicron MR controlled evaluation trial“), VADT („veterans affairs diabetes trial“) und ACCORD („action to control cardiovascular risk...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.